ASH 2024 – CellCentric's myeloma first
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
ASH 2024 preview – multiple myeloma in focus
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Carvykti takes off
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
